NIKA (Nika Pharmaceuticals) Total Equity: $-0.31 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NIKA Nika Pharmaceuticals Inc NIKA
12 GF Score
Price $0.77
! 3 Warning Signs
View Full Analysis

What is Nika Pharmaceuticals Total Equity?

Nika Pharmaceuticals NIKA 12 Total Equity is $-0.31 Mil as of Mar. 2026. GuruFocus rates NIKA with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

Nika Pharmaceuticals's total equity for the quarter that ended in Mar. 2026 was $-0.31 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Nika Pharmaceuticals Total Equity Historical Data

* Premium members only.

The historical data trend for Nika Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nika Pharmaceuticals Total Equity Chart

Nika Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial -0.02 -0.02 -0.08 -0.22 -0.30

Nika Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.23 -0.25 -0.26 -0.30 -0.31
NIKA
12GF Score
Nika Pharmaceuticals Inc NIKA
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nika Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Nika Pharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=0.021-0.319
=-0.30

Nika Pharmaceuticals's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=0.021-0.332
=-0.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $-0.31 Mil mean?
Nika Pharmaceuticals (NIKA) has a Total Equity of $-0.31 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Nika Pharmaceuticals and its competitors.
Is Nika Pharmaceuticals' Total Equity too high?
Nika Pharmaceuticals' current Total Equity is $-0.31 Mil. Overall, Nika Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Nika Pharmaceuticals' Total Equity compare to EOLS and EBS?
Nika Pharmaceuticals' Total Equity of $-0.31 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Nika Pharmaceuticals and its competitors. Nika Pharmaceuticals's current Total Equity is $-0.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nika Pharmaceuticals stock overvalued right now?
Nika Pharmaceuticals (NIKA) has a current Total Equity of $-0.31 Mil. The current Total Equity is $-0.31 Mil. Nika Pharmaceuticals' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Nika Pharmaceuticals (NIKA), the current Total Equity is $-0.31 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nika Pharmaceuticals Business Description

Address 2269 Merrimack Valley Avenue, Henderson, NV, USA, 89044
Nika Pharmaceuticals Inc is a company involved in development and distribution of a variety of pharmaceutical products, including dietary supplements and antiviral drugs. It has acquired the exclusive rights for production and distribution of the dietary supplements Physiolong and Carotilen, as well as the drug TNG, which has been clinically tested on AIDS patients.
12GF Score

Get the complete analysis for NIKA

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.77
Price